Monovalent H5 vaccine based on epitope-chimeric HA provides broad cross-clade protection against variant H5N1 viruses in mice

Antiviral Research

Volumn 105, Issue 1, 2014, Pages 143-151

  He, Fang ^a   Prabakaran, Mookkan ^a   Kumar, Subaschandrabose Rajesh ^a   Tan, Yunrui ^a   Kwang, Jimmy ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Cross clade; H5N1 AIV; Influenza vaccine; Monovalent

Indexed keywords

AMINO ACID; CHIMERIC ANTIBODY; INFLUENZA VACCINE; MONOVALENT H5 VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; EPITOPE; INACTIVATED VIRUS VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; MONTANIDE ISA 51; MONTANIDE ISA 563; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; SUBUNIT VACCINE; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CLADISTICS; CONTROLLED STUDY; FEMALE; HEMAGGLUTINATION INHIBITION TEST; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA A (H5N1); MDCK CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS NEUTRALIZATION; VIRUS STRAIN; ADJUVANT THERAPY; AMINO ACID SEQUENCE; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; CYTOPATHOGENIC EFFECT; HEMAGGLUTINATION INHIBITION; INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; MDCK CELL LINE; PHYLOGENETIC TREE; SURVIVAL RATE; VIRUS LOAD; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CROSS PROTECTION; DISEASE MODEL; GENETICS; IMMUNOLOGY; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CROSS PROTECTION; DISEASE MODELS, ANIMAL; EPITOPES; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 84897385995     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.03.002     Document Type: Article

References (39)

1. M. Baz, C.J. Luke, X. Cheng, H. Jin, and K. Subbarao H5N1 vaccines in humans Virus Res. 178 1 2013 78 98
2. A.J. Caton, G.G. Brownlee, J.W. Yewdell, and W. Gerhard The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype) Cell 31 2 Pt 1 1982 417 427 (Pubitemid 13178866)
3. G.L. Chen, and K. Subbarao Attacking the flu: neutralizing antibodies may lead to 'universal' vaccine Nat. Med. 15 11 2009 1251 1252
4. M.W. Chen, T.J. Cheng, Y. Huang, J.T. Jan, S.H. Ma, A.L. Yu, C.H. Wong, and D.D. Ho A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses Proc. Natl. Acad. Sci. USA 105 36 2008 13538 13543
5. M.F. Ducatez, J. Bahl, Y. Griffin, E. Stigger-Rosser, J. Franks, S. Barman, D. Vijaykrishna, A. Webb, Y. Guan, R.G. Webster, G.J. Smith, and R.J. Webby Feasibility of reconstructed ancestral H5N1 influenza viruses for cross-clade protective vaccine development Proc. Natl. Acad. Sci. USA 108 1 2011 349 354
6. I. Dukhovlinov, R. Al-Shekhadat, E. Fedorova, L. Stepanova, M. Potapchuk, I. Repko, O. Rusova, A. Orlov, L. Tsybalova, and O. Kiselev Study of immunogenicity of recombinant proteins based on hemagglutinin and neuraminidase conservative epitopes of influenza A virus Med. Sci. Monit. Basic Res. 19 2013 221 227
7. H.L. Forrest, A.M. Khalenkov, E.A. Govorkova, J.K. Kim, G. Del Giudice, and R.G. Webster Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets Vaccine 27 31 2009 4187 4195
8. R.A. Fouchier, and D.J. Smith Use of antigenic cartography in vaccine seed strain selection Avian Dis. 54 1 Suppl 2010 220 223
9. A. Gambotto, S.M. Barratt-Boyes, M.D. de Jong, G. Neumann, and Y. Kawaoka Human infection with highly pathogenic H5N1 influenza virus Lancet 371 9622 2008 1464 1475 (Pubitemid 351618340)
10. B.M. Giles, S.J. Bissel, D.R. Dealmeida, C.A. Wiley, and T.M. Ross Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines Clin. Vaccine Immunol. 19 2 2012 128 139
11. B.M. Giles, and T.M. Ross A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets Vaccine 29 16 2011 3043 3054
12. Y. Guan, L.L. Poon, C.Y. Cheung, T.M. Ellis, W. Lim, A.S. Lipatov, K.H. Chan, K.M. Sturm-Ramirez, C.L. Cheung, Y.H. Leung, K.Y. Yuen, R.G. Webster, and J.S. Peiris H5N1 influenza: a protean pandemic threat Proc. Natl. Acad. Sci. USA 101 21 2004 8156 8161 (Pubitemid 38698070)
13. F. He, Y. Ho, L. Yu, and J. Kwang WSSV ie1 promoter is more efficient than CMV promoter to express H5 hemagglutinin from influenza virus in baculovirus as a chicken vaccine BMC Microbiol. 8 2008 238
14. F. He, and J. Kwang Monoclonal antibody targeting neutralizing epitope on H5N1 influenza virus of clade 1 and 0 for specific H5 quantification Influenza Res. Treat. 2013 2013 360675
15. F. He, R.D. Soejoedono, S. Murtini, M. Goutama, and J. Kwang Complementary monoclonal antibody-based dot ELISA for universal detection of H5 avian influenza virus BMC Microbiol. 10 2010 330
16. S.E. Hensley, S.R. Das, A.L. Bailey, L.M. Schmidt, H.D. Hickman, A. Jayaraman, K. Viswanathan, R. Raman, R. Sasisekharan, J.R. Bennink, and J.W. Yewdell Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift Science 326 5953 2009 734 736
17. H.T. Ho, H.L. Qian, F. He, T. Meng, M. Szyporta, N. Prabhu, M. Prabakaran, K.P. Chan, and J. Kwang Rapid detection of H5N1 subtype influenza viruses by antigen capture enzyme-linked immunosorbent assay using H5- and N1-specific monoclonal antibodies Clin. Vaccine Immunol. 16 5 2009 726 732
18. < http://www.who.int/influenza/human-animal-interface/EN-GIP- 20131008CumulativeNumberH5N1cases.pdf >, 2013.
19. M. Imai, T. Watanabe, M. Hatta, S.C. Das, M. Ozawa, K. Shinya, G. Zhong, A. Hanson, H. Katsura, S. Watanabe, C. Li, E. Kawakami, S. Yamada, M. Kiso, Y. Suzuki, E.A. Maher, G. Neumann, and Y. Kawaoka Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets Nature 486 7403 2012 420 428
20. N.V. Kaverin, I.A. Rudneva, N.A. Ilyushina, N.L. Varich, A.S. Lipatov, Y.A. Smirnov, E.A. Govorkova, A.K. Gitelman, D.K. Lvov, and R.G. Webster Structure of antigenic sites on the haemagglutinin molecule of H5 avian influenza virus and phenotypic variation of escape mutants J Gen. Virol. 83 Pt 10 2002 2497 2505
21. D.J. Laddy, J. Yan, N. Corbitt, D. Kobasa, G.P. Kobinger, and D.B. Weiner Immunogenicity of novel consensus-based DNA vaccines against avian influenza Vaccine 25 16 2007 2984 2989 (Pubitemid 46482729)
22. J.S. Peiris, M.D. de Jong, and Y. Guan Avian influenza virus (H5N1): a threat to human health Clin. Microbiol. Rev. 20 2 2007 243 267 (Pubitemid 46709304)
23. N. Pica, and P. Palese Toward a universal influenza virus vaccine: prospects and challenges Annu. Rev. Med. 64 2013 189 202
24. J.B. Plotkin, J. Dushoff, and S.A. Levin Hemagglutinin sequence clusters and the antigenic evolution of influenza A virus Proc. Natl. Acad. Sci. USA 99 9 2002 6263 6268 (Pubitemid 34493300)
25. M. Prabakaran, F. He, T. Meng, S. Madhan, T. Yunrui, Q. Jia, and J. Kwang Neutralizing epitopes of influenza virus hemagglutinin: target for the development of a universal vaccine against H5N1 lineages J. Virol. 84 22 2010 11822 11830
26. M. Prabakaran, H.T. Ho, N. Prabhu, S. Velumani, M. Szyporta, F. He, K.P. Chan, L.M. Chen, Y. Matsuoka, R.O. Donis, and J. Kwang Development of epitope-blocking ELISA for universal detection of antibodies to human H5N1 influenza viruses PLoS One 4 2 2009 e4566
27. M. Prabakaran, N. Prabhu, F. He, Q. Hongliang, H.T. Ho, J. Qiang, T. Meng, M. Goutama, and J. Kwang Combination therapy using chimeric monoclonal antibodies protects mice from lethal H5N1 infection and prevents formation of escape mutants PLoS One 4 5 2009 e5672
28. N. Prabhu, M. Prabakaran, Q. Hongliang, F. He, H.T. Ho, J. Qiang, M. Goutama, A.P. Lim, B.J. Hanson, and J. Kwang Prophylactic and therapeutic efficacy of a chimeric monoclonal antibody specific for H5 haemagglutinin against lethal H5N1 influenza Antiviral Ther. 14 7 2009 911 921
29. E. Prieto-Lara, and A. Llanos-Mendez Safety and immunogenicity of prepandemic H5N1 influenza vaccines: a systematic review of the literature Vaccine 28 26 2010 4328 4334
30. C.A. Russell, T.C. Jones, I.G. Barr, N.J. Cox, R.J. Garten, V. Gregory, I.D. Gust, A.W. Hampson, A.J. Hay, A.C. Hurt, J.C. de Jong, A. Kelso, A.I. Klimov, T. Kageyama, N. Komadina, A.S. Lapedes, Y.P. Lin, A. Mosterin, M. Obuchi, T. Odagiri, A.D. Osterhaus, G.F. Rimmelzwaan, M.W. Shaw, E. Skepner, K. Stohr, M. Tashiro, R.A. Fouchier, and D.J. Smith Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses Vaccine 26 Suppl 4 2008 D31 D34
31. D.A. Shore, H. Yang, A.L. Balish, S.S. Shepard, P.J. Carney, J.C. Chang, C.T. Davis, R.O. Donis, J.M. Villanueva, A.I. Klimov, and J. Stevens Structural and antigenic variation among diverse clade 2 H5N1 viruses PLoS One 8 9 2013 e75209
32. J. Stevens, O. Blixt, T.M. Tumpey, J.K. Taubenberger, J.C. Paulson, and I.A. Wilson Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus Science 312 5772 2006 404 410
33. H. Sun, Y. Sun, J. Pu, Y. Zhang, Q. Zhu, J. Li, J. Gu, K.C. Chang, and J. Liu Comparative virus replication and host innate response in human cells infected with 3 prevalent clades 2.3.4, 2.3.2 and 7 of highly pathogenic avian influenza H5N1 viruses J Virol. 2013
34. Y. Watanabe, M.S. Ibrahim, H.F. Ellakany, N. Kawashita, R. Mizuike, H. Hiramatsu, N. Sriwilaijaroen, T. Takagi, Y. Suzuki, and K. Ikuta Acquisition of human-type receptor binding specificity by new H5N1 influenza virus sublineages during their emergence in birds in Egypt PLoS Pathog. 7 5 2011 e1002068
35. The World Health Organization Global Influenza Program Surveillance Network Evolution of H5N1 avian influenza viruses in Asia Emerg. Infect. Dis. 11 10 2005 1515 1521
36. WHO/OIE/FAO H5N1 Evolution Working Group Toward a unified nomenclature system for highly pathogenic avian influenza virus (H5N1) Emerg. Infect. Dis. 14 7 2008 e1
37. F. Wu, J.H. Huang, X.Y. Yuan, W.S. Huang, and Y.H. Chen Characterization of immunity induced by M2e of influenza virus Vaccine 25 52 2007 8868 8873 (Pubitemid 350199590)
38. J.X. Yang, L.W. Ju, L.F. Jiang, Q. Shi, Q.W. Jiang, Y.Y. Zhang, Y.B. Zhou, H.G. Shen, and Y.Y. Tan Type and subtype distribution of influenza virus and genetic evolution of hemagglutinin in Shanghai area in duration of 2004-2008 Zhonghua Yu Fang Yi Xue Za Zhi 43 4 2009 305 308
39. M. Younan, M.K. Poh, E. Elassal, T. Davis, P. Rivailler, A.L. Balish, N. Simpson, J. Jones, V. Deyde, R. Loughlin, I. Perry, L. Gubareva, M.A. ElBadry, S. Truelove, A.M. Gaynor, E. Mohareb, M. Amin, C. Cornelius, G. Pimentel, K. Earhart, A. Naguib, A.S. Abdelghani, S. Refaey, A.I. Klimov, R.O. Donis, and A. Kandeel Microevolution of highly pathogenic avian influenza A (H5N1) viruses isolated from humans, Egypt, 2007-2011 Emerg. Infect. Dis. 19 1 2013 43 50